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Abstract
Background: Fanconi anemia (FA) is an inherited genomic instability disorder with congenital and developmental
abnormalities, bone marrow failure and predisposition to cancer early in life, and cellular sensitivity to DNA interstrand
crosslinks.
Case presentation: A fifty-one-year old female patient, initially diagnosed with FA in childhood on the basis of classic
features and increased chromosomal breakage, and remarkable sun-sensitivity is described. She only ever had mild
haematological abnormalities and no history of malignancy. To identify and characterise the genetic defect in this lady,
who is one of the oldest reported FA patients, we used whole-exome sequencing for identification of causative
mutations, and functionally characterized the cellular phenotype. Detection of the novel splice site mutation c.793-2A > G
and the previously described missense mutation c.1765C > T (p.Arg589Trp) in XPF/ERCC4/FANCQ assign her as
the third individual of complementation group FA-Q. Ectopic expression of wildtype, but not mutant, XPF/
ERCC4/FANCQ, in patient-derived fibroblasts rescued cellular resistance to DNA interstrand-crosslinking agents.
Patient derived FA-Q cells showed impaired nuclear excision repair capacity. However, mutated XPF/ERCC4/
FANCQ protein in our patient’s cells, as in the two other patients with FA-Q, was detectable on chromatin, in
contrast to XP-F cells, where missense-mutant protein failed to properly translocate to the nucleus.
Conclusions: Patients with FA characteristics and UV sensitivity should be tested for mutations in XPF/ERCC4/
FANCQ. The missense mutation p.Arg589Trp was previously detected in patients diagnosed with Xeroderma
pigmentosum or Cockayne syndrome. Hence, phenotypic manifestations associated with this XPF/ERCC4/ FANCQ mutation
are highly variable.
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Background
Fanconi anemia (FA) is a rare inherited genomic instability
disorder with remarkable clinical and genetic heterogen-
eity. Whilst variable, typical features include developmen-
tal anomalies and malformations, most commonly growth
retardation, cutaneous pigment displacement and radial
ray defects. FA features also comprise early-onset bone
marrow failure and cancer predisposition, specifically for
acute myelogenous leukemia and head and neck squa-
mous cell carcinoma [1, 2]. Causative mutations in any
one of 22 FA genes (FANCA, -B, -C, -D1, -D2, -E, -F, -G,
-I, -J, -L, -M, -N, -O, -P, -Q, -R, -S, -T, -U -V-and W) have
been reported, whose corresponding proteins function to-
gether in a replication-dependent DNA interstrand cross-
link (ICL) repair pathway [3, 4].
XPF, alias ERCC4 or FANCQ is the catalytic subunit
of a heterodimer with ERCC1 that forms a structure-
specific DNA repair endonuclease on the SLX4/FANCP
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scaffold. In the FA/BRCA pathway its activity is respon-
sible for the nucleolytic strand incision 5′ to ICLs, which
is a prerequisite for unhooking of a crosslink [5]. XPF/
ERCC4/FANCQ also acts in the nucleotide excision
repair (NER) pathway, independently of SLX4 [6], to
remove intrastrand helix-distorting lesions from DNA,
such as UV light-induced photoadducts. In fact, XPF/
ERCC4/FANCQ mutations have mainly been identified
in patients with Xeroderma pigmentosum (XP) of com-
plementation group F (XP-F) [5, 7], and later in an indi-
vidual with the XFE progeroid syndrome [8]. Recently,
in two individuals (FA104 and 1333) mutations in XPF/
ERCC4/FANCQ have been found to cause classic FA [9].
Clinical features of XP and Cockayne syndrome (CS)
were described in FA due to XPF/ERCC4/FANCQ muta-
tions in another patient (XPCS1CD), and reconciled
clinically impaired ICL repair with deficient NER [10].
Here we present one of the oldest reported individuals
to be affected by FA, whom we identified as the third
FA-Q patient due to bi-allelic XPF/ERCC4/FANCQ muta-
tions. As the missense mutation p.Arg589Trp here impli-
cates FA, opposed to XP or CS in other cases, we
investigate and discuss biological and clinical implications.
Case presentation
Clinical course
The diagnosis of FA in a 51-year-old woman (at the time
of this report, patient 3104) was made when she pre-
sented at the age of seven with thrombocytopenia and
bilateral radial ray abnormalities including right thumb
absence and severe left hypoplasia (Fig. 1a), and in-
creased sensitivity to DNA interstrand-crosslinking
agents of her cells (data no longer available). Other features
of FA included mild facial anomalies (Fig. 1a−c), short stat-
ure, microcephaly and skin pigmentation changes. The pa-
tient is the younger of two sisters of an unrelated White
British couple, both over 70 and well, with an unremarkable
past medical and family history. The patient is married and
worked for a long time in administrative and secretarial po-
sitions. During her adult life borderline thrombocytopenia
and macrocytosis persisted. Further details with respect to
clinical manifestations and management are provided in
Table 1. Since she was referred to our service in her fifth
decade, her hypo-cellular bone marrow remained without
features of dysplasia or clonal cytogenetic aberrations
(current platelet count 117 × 109/L, MCV 109 fl). Notably,
she reported to burn very easily in the sun, and avoided sun
exposure all her life. She developed so far neither bone
marrow failure nor malignancy.
Cell culture
Cyclosporine A was used to establish Epstein-Barr virus
(EBV)-transformed lymphoblastoid cell lines (LCL) [11].
Peripheral blood lymphoblasts were grown in RPMI
1640 medium supplemented with GlutaMAX (Gibco)
and 15% fetal bovine serum (FBS). Primary fibroblasts of
the patient concerned were cultured in Amniopan
medium (PAN Biotech), while SV40 large T antigen-
immortalized fibroblasts were maintained in MEM with
GlutaMAX and 10% FBS. For retrovirally transduced fi-
broblasts 10% Tet System Approved FBS (Clontech
Laboratories) was used. All cultures were maintained in
incubators with 5% CO2. Cells were exposed to 40 ng/μl
mitomycin C (MMC) for 16 h prior to immunofluores-
cence analysis of RAD51 foci, immunoblotting or cell
fractionation studies. Cell lines from disease and normal
controls were maintained as previously reported [9].
Chromosome studies
Cytogenetic assays were performed on whole blood
cultures to assess spontaneous and MMC-induced
breakage rates. MMC at indicated final concentrations
was added to blood samples as a G0 pulse before culture
initiation. After 1 h the cells were washed and transferred
to fresh complete RPMI 1640 medium. Lymphocytes were
stimulated with phytohemagglutinin (PHA). The cultures
were incubated at 37 °C and harvested after 72 h.
Chromosome preparations were made by the air drying
method [12]. Solid (Giemsa)-stained metaphases were
examined for chromatid and chromosome type damage,
and the results were compared to age and sex-matched
normal controls.
Cell cycle analysis
PHA-stimulated lymphocytes or primary fibroblasts
were cultured untreated for 72 h or continuously ex-
posed to MMC. Mono- or bivariate (BrdU-Hoechst
33,258/Ethidium bromide) cell cycle analysis was per-
formed on a triple-laser-equipped flow cytometer (LSRII,
BD Biosciences). Data were analyzed using the MPLUS
AV software package (Phoenix Flow Systems) [13].
Nucleic acid isolation and cDNA synthesis
A modified salting-out technique [14] or the GeneJET
Genomic DNA Purification Kit (Thermo Fisher) were
used for isolation of genomic DNA (gDNA). For total
RNA isolation we employed the High Pure RNA Isolation
Kit (Roche) while transcription into cDNA was performed
by SuperScript Reverse Transcriptase (Invitrogen).
Quantitative PCR
For relative quantification of mRNA expression levels,
allele-specific primers were designed (WT for: 5’-GAC
GCAGAGCTAACCTTTGTTC-3′; c.1765C > T MUT
for: 5′- GACGCAGAGCTAACCTTTGTTT-3′; WT/
MUT rev: 5′- GTTCCTCAGTTGAACCTCCGTA-3′).
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Fig. 1 (See legend on next page.)
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For the detection of exon 5 skipping due to
c.793-2A > G primer sequences were as follows: WT
for: 5′- TCTGGAATCTCTGAGAGCAACG-3′, WT
rev: 5′- AACATCGAGGTGCTGGAGTC-3′, MUT
for: 5′- ATAACCCATCGCTTGAAGTGGA-3′, MUT
rev: 5′- CAAGAA\ACAGCCAACCTTGTCA-3′. The
PCR reaction was performed with HOT FIREPol®
EvaGreen® qPCR Mix Plus (Solis BioDyne) on an ABI
ViiaTM 7 System (Applied BiosystemsTM). Evaluation
of melting curves and amplification plots, and relative
quantification (RQ) was done with the
QuantStudioTM Real-Time PCR Software v1.2.4
(Applied BiosystemsTM) using the ΔΔCt method.
Each sample was analyzed in technical triplets.
Retroviral complementation
Transduction with different retroviral vectors containing
XPF/ERCC4/FANCQ cDNA constructs or mock was
performed according to standard protocols [15, 16].
Transduced immortalized fibroblasts were analyzed for
their sensitivity. Aliquots of 20,000 cells per well were
seeded in 6-well culture plates and grown at the indi-
cated concentrations of MMC. After eight days cell via-
bility was determined by image cytometry using
(See figure on previous page.)
Fig. 1 Portraits of FA-Q patient 3104 at different age, and characterization of her genetic and cellular defects. a: Typical FA puppet-like face, small head,
light brown hair, absence of the right and severe hypoplasia of the left thumb (arrows) at about 15 months. b: High slanting eye lids and beginning
freckling of the face at age 12 years. c: Low-set auricles, early hair graying and actinic keratosis-like skin changes with erythema, atrophy and patchy
pigmentation in her fifth decade. d: A heterozygous substitution of adenine with guanine (asterisk) 2 bp upstream of exon 5 in the XPF/ ERCC4/FANCQ
gene was maternally inherited. e: The mutation shown in (d) leads to aberrant splicing (upper panel). Gel extraction and sequence analysis of a major
splice product reveals skipping of exon 5 (lower panel). f: The second heterozygous FANCQ mutation c.1765C > T (asterisk) is located in exon 8 and
was paternally inherited. g: 3104 fibroblasts transduced with mock vector (green line) or with vector containing XPF/ ERCC4/FANCQ with the missense
mutation c.1765C > T (red line) are MMC-sensitive, though not quite to the degree of fibroblasts from an FA-B patient serving as a control (black line).
Complementation of 3104 fibroblasts with wildtype FANCQ (FANCQWT, blue line) restores MMC resistance. Error bars designate SDs of three experi-
ments. LC50 levels are indicated by dotted lines of corresponding colors; they equal 42.6 ± 5.7 nM for 3104 +mock, 52.8 ± 2.7 nM for 3104 + FANCQ
MUT
and 20.7 ± 2.4 nM for FA-B fibroblasts. The survival rates of 3104 + FANCQMUT and 3104 +mock are not significantly different, however the proportions
for all concentrations (except 0) of these curves and 3104 + FANCQWT are different with p < 0.001. h: Immunoblot using fibroblast extracts from the
FA-Q cell line 3104 and of the previously reported FA-Q cell line 1333 [9] with different FANCQ missense mutations showing immunoreactive residual
FANCQ protein of normal size but reduced abundance in comparison to a normal (CON) and a FANCD2-deficient (FA-D2) control. One thousand three
hundred thirty-three reveals an additional FANCQ band resulting from a truncating mutation on the second allele. Loading control: tubulin. i: Cell
fractionation demonstrates residual mutant FANCQ protein in 3104 cells detectable in the chromatin fraction. j and k: Normal ERCC1-XPF interactions
in 3104 transformed fibroblasts. ERCC1 (j) or XPF (k) were immunoprecipitated with antibodies against ERCC1 or XPF, respectively. Unspecific bands
are marked by asterisks while the visible antibody heavy chain is indicated by an arrow
Table 1 Clinical manifestation of affected systems and clinical management in the FA-Q patient
Affected System Clinical manifestations Management
Growth Low birthweight 2010 g; Short stature; Microcephaly
Skeletal abnormalities Right thumb absent
Left thumb hypoplastic
Hip dislocation
Tibia torsion
Pollicizations at age 3 and 4
Conservative
Internal rotation osteotomy age 25
Gastrointestinal Ectopic anus
Fatty liver with persistently
elevated liver enzymes
Monitoring
Urogenital Crossed kidney fusion ectopia, both kidneys on the right Surveillance of kidney function only
Haematological Thrombocytopenia with macrocytosis
Mild bone marrow hypoplasia without evidence of clonal chromosomal
aberrations
Surveillance only
Endocrine and reproductive
health
Diabetes Type 1, age 42
No children
Menopause age 29
Low dose insulin (~0.2 U/kg/ day)
Hormone replacement therapy since
age 32
Skin Café-au-lait spots
Lifelong sun sensitivity with severe sunburn and blistering after minimal sun
exposure
Meticulous sun avoidance and skin
protection
Hearing Sensorineural hearing loss increasingly relevant age 45 Hearing aid
Brain Cerebral and cerebellar atrophy
Small pituitary gland Microangiopathic white matter signal changes
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VitaBright-48 and propidium iodide staining on a
NucleoCounter NC-250 instrument (ChemoMetec A/S).
Lymphoblast survival
LCLs were grown in T25 cell culture flasks at concentra-
tions of 0–1000 nM MMC for eight days. Cell viability
was analyzed by propidium iodide exclusion and assayed
by flow cytometry.
Immunofluorescence
Nuclear RAD51 focus formation was analyzed in fibro-
blasts grown on glass chamber slides (Sarstedt). Cells
were washed with PBS and subsequently fixed in 4%
(vol/vol) paraformaldehyde in PBS for 15 min at room
temperature. Thereafter they were exposed to ice-cold
100% methanol and kept on ice for 30 min. Blocking of
non-specific antibody binding sites was accomplished
with 20% (vol/vol) FBS in PBS for 30 min at room
temperature. Rabbit anti-RAD51 (1:800; ab63801,
Abcam) served as primary antibody, to be detected by
Alexa 594-conjugated anti-rabbit secondary antibody
(1:2000; A11037, Molecular Probes/Life Technologies).
ProLong Gold Antifade Mountant with DAPI (Thermo
Fisher) was used for counter-staining and as mounting
medium. Foci-positive cells (>5 foci/nucleus) were scored
by fluorescence microscopy (Axiovert 40C, Zeiss).
Immunoblot analysis
Aliquots of 40 μg whole protein extracts from cultured
cells were loaded on NuPAGE Novex 7% Tris-Acetate
protein gels (Invitrogen). Electrophoresis was carried out
over night at 70 V with constant cooling. Proteins were
transferred using a dry blotting system (iBlot 2, Life
Technologies). FANCD2 isoform immunodetection was
carried out using primary anti-FANCD2 antibody (1:500;
sc-20,022, Santa Cruz) and secondary anti-mouse
IgG-HRP (sc-2005, Santa Cruz) diluted 1:3000. FANCJ
(1:1000; NB100–416, Novus) or vinculin (1:10,000;
ab129002, Abcam) served as loading controls. For
visualization of ERCC4/XPF/FANCQ whole protein ex-
tracts were separated on NuPAGE 4–12% Bis-Tris gels
(Invitrogen). Anti-XPF (1:200; ab17798, Abcam) was
used for immunodetection while Anti-Tubulin (1:1000;
ab44928, Abcam) was employed as loading control.
Luminescence was generated by chemical reaction with
a standard ECL reagent (Millipore Corporation).
Subcellular fractionation
The NE-PER Nuclear and Cytoplasmic Extraction Kit
(Thermo Fisher) was used for extraction of cytoplasmic
proteins while nuclear and chromatin-associated proteins
were isolated by the Subcellular Protein Fractionation Kit
(Thermo Fisher). SDS-PAGE was run on NuPAGE 4–12%
Bis-Tris gels (Invitrogen). For XPF, YY1, tubulin and
histone H3 immunodetection we employed Anti-XPF
(1:200; ab17798, Abcam), Anti-Tubulin (1:1000; ab44928,
Abcam), Anti-YY1 (1:5000; ab199998, Abcam) and Anti--
Histone H3 (1:800; ab1791, Abcam) antibodies. Secondary
antibodies were as above.
Co-Immunoprecipitation
Cell pellets were resuspended in 200 μl lysis buffer
(20 mM Tris-HCl pH 7.4, 10 mM KCl, 140 mM NaCl,
1 mM EDTA, 0.2 mM EGTA, 0,5% Triton X-100, 5%
Glycerol, 0.1 mM PMSF, 0.5 mM DTT, Halt Protease/
Phosphatase Inhibitor Cocktail 1:50) and lysed by sonic-
ation. After centrifugation (14,000×g for 10 min at 4 °C)
and lysate pre-clearing, 500 μl cell lysate with 1 mg/ml
cell total protein was incubated with the primary anti-
body (ERCC1: ab2356, Abcam, 1:150; XPF: ab76948,
Abcam, 4 μg/mg total protein in the lysate) at 4 °C over-
night. 50 μl of pre-washed Protein G Dynabeads
(Thermo Scientific) was added. After incubation for 2 h
at 4 °C, the beads were washed five times using 500 μl
washing buffer (20 mM Tris-HCl pH 7.4, 10 mM KCl,
140 mM NaCl, 1 mM EDTA, 0.2 mM EGTA, 0.1% Tri-
ton X-100, 5% Glycerol, 0.1 mM PMSF, 0.5 mM DTT,
Halt Protease/Phosphatase Inhibitor Cocktail 1:100).
Beads were taken up in 20 μl elution buffer, 4× LDS
sample buffer and 10× reducing agent. Following
incubation for 10 min at 70 °C beads were collected and
the supernatant was loaded on a 4–12% Bis-Tris gel.
Immunodetection was carried out using anti-XPF (1:200;
ab17798, Abcam) or anti-ERCC1 (1:100; sc-17,809, Santa
Cruz) primary antibodies. YY1 (1:5000; ab199998,
Abcam) served as loading control.
UV-C survival
Aliquots of 5000 fibroblasts per well were seeded in
6-well plates. After two days cells were washed with PBS
and irradiated at the indicated doses in quadruplicate
(0 J/m2) or triplicate (others) using an UV-C germicidal
lamp (254 nm; Philips). An UVX Digital Radiometer
(Serial No. E27846, UVP) was used to quantify the exact
UV dose. Control cells were UV irradiated simultan-
eously to serve as an internal control. After another five
days, before the non-irradiated cultures reached
confluency, cells were pulse-labeled with
[methyl-3H]-thymidine (40–60 Ci/mmol; 5 μCi/ml;
Amersham Biosciences)-containing medium for 3 h,
washed with PBS and chased for 15 min in medium
without 3H–thymidine. Finally cells were lysed in
0.25 M NaOH. Each lysate was counted with 7.5 ml
Hionic Fluor scintillation fluid in a liquid scintillation
counter (Packard) for 10 min. The results obtained from
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irradiated plates were expressed as percentages of non--
irradiated plates (set 100%) and plotted [17].
UV-C-induced UDS and RRS
Unscheduled DNA synthesis (UDS) and recovery of
RNA synthesis (RRS) experiments after UV-C irradiation
were done with mixed cell populations [7]. C5RO wild-
type (WT) fibroblasts were incubated and preloaded
with polystyrene beads of 2 μm diameter for three days,
then mixed with the patient (3104 or 1333) fibroblasts
and seeded on coverslips. Two days later adherent cells
were washed with PBS and UV-C irradiated at 16 J/m2.
Thereafter they were incubated for 3 h in medium
containing 0.1 μM 5-ethynyl-2′-deoxyuridine (EdU;
Invitrogen). Afterwards they were washed with PBS, in-
cubated with medium without EdU for 15 min, washed
with PBS, fixed with 3.7% formaldehyde in PBS contain-
ing 0.5% Triton for 15 min and washed two times with
PBS again. The cells were incubated for 30 min with
fluorescent dye-coupling buffer containing 10 mM
CuSO4 and Alexa Fluor 594 azide (Qlick-iTTM; Invitro-
gen). After washing with PBS, cells were mounted in
Vectashield Antifade Mounting Medium with DAPI
(Vector Laboratories). For RRS studies cells were treated
identically as for UDS experiments, but 16 h after irradi-
ation incubated with culture medium containing 0.1 μM
5-ethynyl-uridine (EU) for 2 h.
Visual light distinguished WT cells that contained
beads in their cytoplasm from patient cells that did not.
On micrographs DAPI is the blue signal that stains nu-
clei. Red is the UDS (or RRS) signal; it is much brighter
in WT than in patient cells. UDS and RRS levels are
expressed as the average fluorescence intensity in the
nucleus of patient vs. WT cells (set at 100%).
Statistics
An unpaired two-tailed Student’s t test was used to com-
pare the results of qPCR analyses. A p value less than
0.05 was considered significant; *p < 0.05, **p < 0.01, ***p
< 0.001.
Results
Chromosome breakage studies from peripheral lympho-
cyte culture of the patient confirmed FA at ages 7, 33
and 49, and demonstrated increased levels of spontan-
eous damage, and in response to MMC (Additional file 1:
Table S1, results of the analysis carried out age 7 are no
longer available). In primary fibroblast cultures a spon-
taneous and MMC-induced G2-phase arrest was ob-
served (Additional file 1: Figure S1A). Also peripheral
blood lymphocyte cultures showed G2-phase accumula-
tion within the FA-range, excluding mosaicism in the
hematopoietic system (Additional file 1: Figure S1B).
Functional analysis of FANCD2 ubiquitination in 3104
fibroblasts demonstrated both FANCD2 isoforms
(Additional file 1: Figure S1C), indicating a mutation in
an FA gene downstream of those encoding the FA core-
and FANCD2/FANCI-complex. RAD51 foci developed
normally after exposure to MMC in both 3104 fibro-
blasts and lymphoblasts (Additional file 1: Figure S1D),
excluding the post-FANCD2 groups FA-D1, -N and -O,
−R, –S, and -U. WES identified two mutations in the
XPF/ERCC4/FANCQ gene, which were confirmed by
Sanger sequencing. A single nucleotide substitution lo-
cated two base pair upstream of exon 5 (c.793-2A > G)
was detected on the maternal allele, affecting a canonical
splice acceptor (Fig. 1d). cDNA sequencing verified aber-
rant splicing. A major splice product revealed exon 5
skipping (Fig. 1e). This event is predicted to result in
premature termination of translation (p.Thr265Valfs*13).
The second change in the XPF/ERCC4/FANCQ se-
quence is the missense mutation c.1765C > T in exon 8
(Fig. 1f ) on the paternal allele, which is listed on the
ExAC-Browser with a minor allele frequency of 0.0066%.
It substitutes a highly conserved amino acid residue
(p.Arg589Trp) in the SF2 helicase-like domain. This mu-
tation has previously been reported in two XP-F patients
(XP24BR and XP32BR) [18], one patient with XP with
neurodegeneration (AS871) [5], and an individual show-
ing an intermediate XP/CS phenotype and features of
FA (XPCS1CD) [10]. Expression of both mutations in
mRNA was re-confirmed by qPCR (Additional file 1:
Figures S1E and F). Complementation of 3104 fibro-
blasts by wildtype, but not Arg589Trp-mutant XPF/
ERCC4/FANCQ rescued MMC resistance, providing evi-
dence that the mutations of XPF/ERCC4/FANCQ cause
the cellular FA phenotype (Fig. 1g). Premature termin-
ation of translation due to exon 5 skipping would result
in a truncated protein of 31.4 kDa. However, on XPF/
ERCC4/FANCQ immunoblot analysis of 3104 fibroblasts
only one low signal intensity band of approximately
100 kDa was detected (Fig. 1h), suggesting the presence
of residual mutant XPF/ERCC4/FANCQ protein of nor-
mal size but reduced abundance. Dilution studies dem-
onstrated that XPF/ERCC4/FANCQ residual protein
with the Arg589Trp mutation is present at approxi-
mately a 1:15th the level of wildtype XPF/ERCC4/
FANCQ protein (Additional file 1: Figure S1G). How-
ever, it is difficult to tell the individual contributions of
mutant transcript and protein instability to this reduc-
tion. Fractionation studies of 3104 fibroblasts showed
that residual full-length XPF/ERCC4/FANCQ protein
was detectable in the nucleus (Fig. 1i), while in cells
from XP-F or XFE patients the mutant XPF/ERCC4/
FANCQ appears to be mislocated and not to be part of
the XPF-ERCC1 complex, presumably as a consequence
of XPF protein misfolding [19].
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In addition to ICL repair, NER activity was also im-
paired in 3104 fibroblasts. Cell survival after UV-C ir-
radiation was reduced (Fig. 2a) (LC50 = 2.8 J/m
2), as it
was the case in fibroblasts from an XP-F patient with
known UV sensitivity and a mild clinical phenotype
(LC50 = 2.2 J/m
2) [20], and FA-Q 1333 fibroblasts as pre-
viously reported [9]. Fibroblasts from the unique XFE
patient [8] showed much higher sensitivity (LC50 = 1.3 J/
m2). Both global genome NER (GG-NER) and
transcription-coupled NER (TC-NER) were affected in
cells from patient 3104. Unscheduled DNA synthesis
(UDS) and recovery of RNA synthesis (RRS) in 3104 fi-
broblasts after UV irradiation were more than 80% de-
creased compared to controls (Fig. 2b-d), to similar
levels as for FA1333 fibroblasts was previously reported
[9] and is shown here again (Fig. 2c and d). Fibroblasts
from an XP-F patient with mild clinical UV-light sensi-
tivity (XP42RO) [7] also exhibited comparable reduction
of UDS and RRS rates, whereas fibroblasts from the XPE
patient (XP51RO) had even lower activity (Fig. 2c and
d). In contrast, 3104 cells were more MMC-sensitive
than 1333 cells (Fig. 2e).
Fig. 2 (See legend on next page.)
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Discussion and conclusion
Long-term observations and genotype/phenotype corre-
lations in rare variants of DNA-repair disorders unlock a
potential for understanding gene function and specific
effects in the DNA-damage response network. Here we
describe one of the oldest FA patients reported, and the
first case who gave a strong history of UV-light sensitiv-
ity, which was confirmed on the cellular level. Hence,
UV sensitivity can be a feature of FA-Q, and the patient’s
perception might be the clinical diagnostic clue for com-
plementation group assignment and mutation detection
in unclassified FA patients. From a hematological per-
spective she has done remarkably well, particularly as
she has radial ray malformations which are often associ-
ated with early hematological problems [21].
The Arg589Trp mutation observed in individual 3104
appears to be associated with mislocalization of XPF/
FANCQ/ERCC4 protein in XP-F cells, where missense-
mutant protein failed to properly translocate to the nu-
cleus [19]. Therefore, the DNA repair defect in XP with
this mutation is at least in part likely due to mislocalized
protein that still interacts with ERCC1, irrespective of its
subcellular localization [19]. We performed co-
immunoprecipitation experiments using anti-ERCC1 or
anti-XPF antibodies. Both ways, we were able to confirm
the interaction in 3104 fibroblasts. In contrast to the lit-
erature [19], residual mutant XPF/FANCQ/ERCC4 of
patient 3104 reported here was detectable with chroma-
tin, as previously described for both other reported
FA-Q-associated mutations Leu230Pro and Arg689Ser
[9], where an interaction of missense-mutant XPF/
FANCQ/ERCC4 proteins with the scaffolding protein
SLX4/FANCP and its dimeric partner ERCC1 was iden-
tified. Hence, the loss of mutant protein interactions that
is critical for the FA-phenotype in FA-Q patients seems
unlikely, as Arg589Trp should have the same effect also
in XP-F patients. Additional factors modulating the
clinical phenotype, which are relevant for FA-Q patients
could include a mechanism allowing a proportion of
mutant protein to escape misfolding. It will be important
to determine if natural chaperones play a role in rescu-
ing XPF/FANCQ/ERCC4 conformational defects, as in
other protein-misfolding diseases, to pave the way clinic-
ally from XP or CS to FA [21]. The concept of manipu-
lating XP, CS, or XFE therapeutically by targeting
nuclear re-localization of mutant XPF-ERCC1 as previ-
ously suggested [19], e.g. by pharmaceutical chaperones,
is questioned by our study, as the problem with ICL re-
pair may remain. The reverse, however, targeting inter-
actions or functions of XPF/FANCQ/ERCC4, a key
protein at the intersection of DNA repair pathways,
could disable NER and ICL repair functions at the same
time and might represent a promising approach to over-
come chemo-resistance in malignant disease [22].
In the two other reported FA-Q patients FA104 and
1333 both second XPF/FANCQ/ERCC4 mutations are
null alleles [9]. In XPCS1CD the missense mutation
p.Cys236Arg confers the XPCS phenotype by conveying
insufficient NER activity, but fails to provide endonucle-
ase activity for ICL removal, being a functional null al-
lele in this respect [10]. In the FA patient presented
here, the second mutation affects a canonical splice ac-
ceptor site (c.793-2A > G) resulting in exon 5 skipping,
frameshift and predicted protein truncation. We show
that the mutant transcript is relatively unstable and can
be stabilized with cycloheximide (Additional file 1:
Figure S1F). Moreover, we demonstrate that residual
abridged XPF/FANCQ/ERCC4 protein is absent (Fig. 1h)
such that this splice site mutation can be regarded as a
null allele. In addition there is no cryptic splice acceptor
nearby that could restore the reading frame.
Pathogenicity of the splice mutation is underscored by
the fact that there is neither a listed transcript isoform
lacking exon 5 sequence nor a reported alternative
(See figure on previous page.)
Fig. 2 ERCC4/XPF/FANCQ (missense) mutations and their effects. a: Dose-response curves of FA-Q fibroblasts 3104 (red) compared with previously reported
1333 (blue), XFE (XP51RO; orange) and XP-F fibroblasts (XP23OS; green) reveal different degrees of UV-C sensitivity on survival compared with normal control
fibroblasts (black) (means ± SEMs). LC50 levels are indicated by the dashed lines of corresponding colors; they equal 5.7 J/m
2 for control cells, 2.8 J/m2 for 3104,
1.5 J/m2 for 1333, 2.2 J/m2 for XP23OS and 1.3 J/m2 for XP51RO. All mentioned cells represent primary fibroblasts. b: NER activity of 3104 FA-Q primary
fibroblasts assayed ex vivo. UDS (upper panel) was measured by incorporation of 5-ethynyl-deoxyuridine (EdU), RRS (lower panel) by incorporation of 5-ethynyl-
uridine (EU). Mixed-in wildtype (WT) fibroblasts preloaded with polystyrene beads (not depicted) served as internal control. DAPI as nuclear counterstain for all
cells. UDS and RRS signals were quantified from 20 to 40 random nuclei. c: UDS levels of control fibroblasts (grey) compared to FA-Q 3104 (red), 1333 (blue),
XFE (orange) and XP-F (green) fibroblasts (means ± SEMs, brackets indicates levels os significance). d: RRS levels of control fibroblasts (grey) compared to FA-Q
3104 (red), 1333 (blue), XFE (orange) and XP-F (green) fibroblasts (means ± SEMs, brackets indicates levels os significance). e: Dose-response curves of 3104 (red;
means ± SEMs) and two previously reported FA-Q lymphoblast lines (FA104, green; 1333, blue) exposed to MMC show different degrees of sensitivity
compared to normal control lymphoblasts (black). LC50 levels are indicated by dashed lines of corresponding colors and equal 210 nM MMC for the control,
80 nM MMC for 1333, 42 nM MMC for 3104 and 24 nM MMC for FA104. f: Combinations (brackets) of the biallelic mutations in all XP-F, CS, XPCS(FA) and XFE
patients with p.Arg589Trp (shaded) (above) and of the biallelic mutations in the three reported FA-Q patients (below) are depicted relative to location in the
ERCC4/XPF/FANCQ protein domain structure [14]. The predicted mutational effects on the protein level are shown in bold letters together with the
corresponding patient designations listed below. Individuals with XP-F include XP24BR, XP32BRand AS871, with XFE include XP51RO, with XPCS(FA) include
XPCS1CD, and with FA-Q include 3104, FA104 and 1333 (3104 highlighted in red). The phenotypic severity of disease in patients with XP, CS, XPCS(FA), or FA-Q
carrying one heterozygous p.Arg589Trp mutation is indicated above the brackets
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ERCC4/XPF/FANCQ splicing product that involves
skipping of exon 5. Our findings imply that the common
basis of all FA-Q cases to date is compound heterozy-
gosity for one null and one hypomorphic missense mu-
tation in XPF/FANCQ/ERCC4, which facilitates the
retention of residual mutant protein capable of chroma-
tin relocation and the provision of NER activity [9],
possibly providing the genetic basis for long-term
survival of certain FA-Q patients.
Additional file
Additional file 1: Figure S1. and Table S1. (DOCX 4108 kb)
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